Trial Profile
A multicenter, retrospective study investigating the safety and efficacy of Cytotect(R)CP as a salvage therapy in patients with cytomegalovirus-infection after allogeneic hematopoietic cell transplantation
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 23 Apr 2018
Price :
$35
*
At a glance
- Drugs Cytomegalovirus immune globulin (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- 23 Apr 2018 New trial record
- 13 Apr 2018 Results published in the Bone Marrow Transplantation